The Bullous Pemphigoid drugs in development market research report provides comprehensive information on the therapeutics under development for Bullous Pemphigoid, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bullous Pemphigoid. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Bullous Pemphigoid by 11 companies/universities/institutes. The top development phase for Bullous Pemphigoid is phase ii with four drugs in that stage. The Bullous Pemphigoid pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bullous Pemphigoid pipeline products market are: Amgen, Johnson & Johnson and Chugai Pharmaceutical.
The key targets in the Bullous Pemphigoid pipeline products market include IgG Receptor FcRn Large Subunit p51, Interleukin 4 Receptor Subunit Alpha, and Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b.
The key mechanisms of action in the Bullous Pemphigoid pipeline product include IgG Receptor FcRn Large Subunit p51 Antagonist with two drugs in Phase III. The Bullous Pemphigoid pipeline products include five routes of administration with the top ROA being Intravenous and four key molecule types in the Bullous Pemphigoid pipeline products market including Monoclonal Antibody, and Small Molecule.
Bullous Pemphigoid overview
Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatories and immunosuppressants.
For a complete picture of Bullous Pemphigoid’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
